通过通过核因子-κBB下调SOX6表达来减少急性心肌梗塞中的心力衰竭
Alternative therapies in health and medicine
|May 31, 2024
概括
下调SRY-Box转录因子6 (SOX6) 通过影响核因子-κB (NF-κB) 途径,有助于减少急性心肌梗塞 (AMI) 后的心力衰竭 (HF). 这为早期诊断和治疗提供了洞察力.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 在急性心肌梗塞 (AMI) 之后的心力衰竭 (HF) 带来了重大的临床挑战.
- 了解AMI中HF背后的分子机制对于开发有效疗法至关重要.
研究的目的:
- 调查SRY-Box转录因子6 (SOX6) 在急性心肌梗塞期间心力衰竭的作用和机制.
- 探索向SOX6用于AMI诱导的HF治疗干预的潜力.
主要方法:
- 在健康个体与AMI患者中对SOX6表达的比较分析.
- 使用缺氧诱导的老鼠心肌细胞 (H9c2细胞) 建立了体外AMI细胞模型.
- 在各种实验条件下评估细胞活力,氧化应激标志物 (ROS,MDA,SOD),亡以及关键蛋白质表达 (原体,纤维素,NF-κB通路组件).
主要成果:
- 在AMI患者和低氧诱导细胞模型中,SOX6的表达都增加了.
- 过度表达SOX6加剧了缺氧引起的损伤,增加了细胞亡和纤维化标志物.
- 降低SOX6的调节,特别是通过si-SOX6,改善了细胞活力,减少了氧化应激和亡,并减弱了纤维化标志物.
- SOX6调制影响了IκBα和p65的酸化,表明NF-κB通路的参与.
结论:
- 降低SOX6表达的调节表明,在急性心肌梗塞中,对心力衰竭有保护作用.
- 保护机制涉及核因子-κB (NF-κB) 信号通路的调节.
- 向SOX6为治疗急性心肌梗塞患者心力衰竭提供了一个潜在的治疗策略.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
02:23Master Transcription Regulators
6.9K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336